Vyvgart Hytrulo® (efgartigimod alfa/hyaluronidase-qvfc) – New dosage form approval
April 10, 2025 - Argenx announced the FDA approval of self-injectable prefilled syringe version of Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc), for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and chronic inflammatory demyelinating polyneuropathy (CIDP).
Top